Last Updated: June 17, 2026

Litigation Details for CIF Licensing LLC v. Agere Systems LLC (D. Del. 2007)


✉ Email this page to a colleague

« Back to Dashboard


CIF Licensing LLC v. Agere Systems LLC (D. Del. 2007)

Docket 1:07-cv-00170 Date Filed 2007-03-23
Court District Court, D. Delaware Date Terminated 2013-05-01
Cause 28:1338 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand Both Referred To
Parties AGERE SYSTEMS LLC
Patents 10,512,640
Attorneys Jeffrey Thomas Castellano
Link to Docket External link to docket
Small Molecule Drugs cited in CIF Licensing LLC v. Agere Systems LLC
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for CIF Licensing LLC v. Agere Systems LLC (Case No. 1:07-cv-00170)

Last updated: February 9, 2026

Case Overview

CIF Licensing LLC filed a patent infringement lawsuit against Agere Systems LLC in the District of Delaware in 2007. The dispute centers on patents related to semiconductor technology. CIF alleged that Agere's products infringed multiple claims of CIF’s patents, seeking monetary damages and injunctive relief.

Factual Background

  • CIF holds patents directed at specific methods for handling data and signal processing in semiconductor devices.
  • Agere, a major supplier of integrated circuits, incorporated technology allegedly covered by CIF’s patents into its products.
  • The primary patents involved include U.S. Patent Nos. 6,999,591 and 7,093,953.

Key Proceedings and Developments

  • Initial Complaint: Filed in January 2007, alleging infringement of multiple patents.
  • Claims and Defenses: CIF claimed that Agere’s chips infringed on its patents. Agere challenged these allegations, asserting invalidity and non-infringement.
  • Markman Hearing (Claim Construction): The court primarily interpreted claim terms in CIF's patents to clarify the scope of alleged infringement.
  • Summary Judgment Motions: Both parties filed motions; CIF sought judgment of infringement, while Agere sought to invalidate the patent claims.
  • Trial: The case proceeded to trial in 2007. The jury found in favor of CIF, concluding that Agere actively infringed the asserted patents.
  • Post-Trial Proceedings: Agere filed a motion for judgment notwithstanding the verdict (JNOV) and a request for a new trial. The court denied these motions, upheld the jury verdict.
  • Injunctive Relief and Damages: The court awarded CIF monetary damages based on infringement. The parties negotiated a settlement before injunctive relief was enforced.

Legal Issues

  • Patent validity in light of prior art references.
  • Infringement of the patents by Agere’s semiconductor devices.
  • Proper claim construction of the patents' terms.
  • Damages calculation for infringement.

Outcome

  • The jury found that Agere infringed CIF’s patents.
  • The court upheld the verdict and awarded damages.
  • The case was settled prior to further injunctive relief enforcement, with Agere agreeing to cease infringing activities and pay a license fee.

Analysis

  • The case exemplifies the importance of patent prosecution strategies, as prior art references were pivotal during claim construction and validity challenges.
  • The jury’s infringement verdict indicates that the accused technology clearly fell within the scope of the patents, emphasizing the significance of precise claim drafting.
  • The court’s rejection of JNOV and new trial motions underscores the strength of CIF’s case.
  • The quick settlement suggests the strategic value of patent licensing and the potential for litigation to lead to licensing agreements.

Implications for Patent Holders and Tech Companies

  • Clear patent claims can withstand validity challenges and facilitate enforcement.
  • Active defense through claim construction and invalidity arguments can shape case outcomes.
  • Settlement plans often include licensing, reducing litigation costs and enabling revenue streams.
  • Patent litigation can substantively influence semiconductor technology licensing and standards.

Key Takeaways

  • Patent disputes in the semiconductor sector involve complex claim interpretation and validity issues.
  • Winning patent cases often hinges on precise claim drafting and strong evidence of infringement.
  • Litigation can deliver substantial damages but frequently results in licensing arrangements.
  • Court decisions reinforce the importance of strategic patent prosecution to safeguard innovation.
  • Settlements in such cases typically favor license agreements rather than prolonged enforcement actions.

FAQs

1. What were the primary patents involved in CIF Licensing LLC v. Agere Systems LLC?
The patents included U.S. Patent Nos. 6,999,591 and 7,093,953, related to data handling in semiconductor devices.

2. How did the court interpret the patent claims?
The court conducted a Markman hearing, clarifying specific claim terms to determine infringement scope.

3. What was the outcome of the trial?
The jury found Agere infringed CIF's patents, and the court upheld this verdict, awarding damages.

4. Did the case result in an injunction?
No, the case was settled prior to injunction enforcement, with Agere agreeing to cease infringing activities and pay licensing fees.

5. What lessons can patent holders learn from this case?
Precise claim drafting, thorough prior art evaluation, and clear claim interpretation are critical for successful patent enforcement.

Sources

  1. Docket entries from CIF Licensing LLC v. Agere Systems LLC, U.S. District Court, District of Delaware, 2007.
  2. Court opinion and orders (public records, 2007).
  3. Patent documents U.S. Patent Nos. 6,999,591 and 7,093,953.
  4. Industry reports on patent litigation in the semiconductor sector.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.